Skip to main content

Table 3 Survival analyses of clinical and biological markers in the recent and the entire cohort

From: Chromosome 1q gain and tenascin-C expression are candidate markers to define different risk groups in pediatric posterior fossa ependymoma

Parameters Overall survival Progression free survival Overall survival
1992–2014 1992–2014 1965–2014
(n = 27) (n = 27) (n = 46)
HR (95 % CI) p-value HR (95 % CI) p-value HR (95 % CI) p-value
Univariate       
Age (years) 0.957 (0.807; 1.135) 0.609 0.930 (0.800; 1.080) 0.324 0.956 (0.875; 1.046) 0.322
Extent of resection
GTR/non-GTR
1.416 (0.173; 11.57) 0.744 5.379 (1.068; 27.08) 0.042 2.876 (1.243; 6.657) 0.010
WHO grade
II/III
7.289 (0.911; 942.8) 0.065 2.421 (0.516; 11.36) 0.249 1.094 (0.448; 2.670) 0.844
TNC
positive/negative
3.739 (0.470; 483.4) 0.184 6.624 (0.841; 856.9) 0.079 9.583 (1.323; 1219) 0.031
LAMA2
positive/negative
1.800 (0.369; 8.776) 0.461 1.701 (0.466; 6.209) 0.416 1.141 (0.497; 2.619) 0.756
Chromosome 1q25
gain/no gain
4.374 (1.085; 17.63) 0.024 4.855 (1.342; 17.56) 0.008 2.474 (0.915; 6.692) 0.065
Multivariable
(n = 26/26/38)
      
TNC
positive/negative
1.872 (0.067; 52.31) 0.712 4.593 (0.505; 608.6) 0.348 3.807 (0.453; 496.7) 0.391
Chromosome 1q25
gain/no gain
4.409 (0.894; 21.74) 0.068 5.204 (1.369; 21.76) 0.024 2.025 (0.745; 5.307) 0.171
Extent of resection
GTR/non-GTR
2.662 (0.767; 9.235) 0.123 2.585 (0.908; 6.235) 0.057 2.135 (0.933; 4.464) 0.062
  1. Hazard ratios (HR), 95 % confidence intervals (CI) and p-values are presented